div class=ts-pagebuttonPage 1button div class=ts-image amp-img class=ts-thumb alt=Page 1: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 2button div class=ts-image amp-img class=ts-thumb alt=Page 2: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 3button div class=ts-image amp-img class=ts-thumb alt=Page 3: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 4button div class=ts-image amp-img class=ts-thumb alt=Page 4: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 5button div class=ts-image amp-img class=ts-thumb alt=Page 5: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails5jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 6button div class=ts-image amp-img class=ts-thumb alt=Page 6: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails6jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 7button div class=ts-image amp-img class=ts-thumb alt=Page 7: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails7jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 8button div class=ts-image amp-img class=ts-thumb alt=Page 8: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails8jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 9button div class=ts-image amp-img class=ts-thumb alt=Page 9: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails9jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 10button div class=ts-image amp-img class=ts-thumb alt=Page 10: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails10jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 11button div class=ts-image amp-img class=ts-thumb alt=Page 11: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails11jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 12button div class=ts-image amp-img class=ts-thumb alt=Page 12: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails12jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 13button div class=ts-image amp-img class=ts-thumb alt=Page 13: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails13jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 14button div class=ts-image amp-img class=ts-thumb alt=Page 14: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails14jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 15button div class=ts-image amp-img class=ts-thumb alt=Page 15: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails15jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 16button div class=ts-image amp-img class=ts-thumb alt=Page 16: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails16jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 17button div class=ts-image amp-img class=ts-thumb alt=Page 17: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails17jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 18button div class=ts-image amp-img class=ts-thumb alt=Page 18: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails18jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 19button div class=ts-image amp-img class=ts-thumb alt=Page 19: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails19jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 20button div class=ts-image amp-img class=ts-thumb alt=Page 20: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails20jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 21button div class=ts-image amp-img class=ts-thumb alt=Page 21: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails21jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 22button div class=ts-image amp-img class=ts-thumb alt=Page 22: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails22jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 23button div class=ts-image amp-img class=ts-thumb alt=Page 23: KMBT C364e-20140403093146 - NCCS€¦ · Page 1 of 2 FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug lclusig company expected to resume src=https:reader033vdocumentsusreader033viewer2022052103603e252149999f423e372c75html5thumbnails23jpg width=142 height=106 layout=responsive amp-img divdiv